$SPHRY News
Last published 1y ago
- 1y agoADIAATNMBPTHCNVIF+12Life Sciences Investor Forum: Now Available for Online ViewingGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and
- 1y agoADIAATNMBPTHCNVIF+12Life Sciences Investor Forum Agenda Announced for June 11th-12thGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
- 4y agoSPHRYStarpharma presents compelling data in Prostate Cancer at ESMOPR NewswireMELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a paten
- 4y agoSPHRYStarpharma signs new DEP® agreement with MSDPR NewswireMELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new DEP® program w
- 4y agoSPHRYStarpharma releases positive DEP® phase 2 interim results in prostate cancerPR NewswireMELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100% of evaluabl
- 5y agoSPHRYUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatmentsPR NewswireMELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a
- 5y agoSPHRYStudy Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge ModelPR NewswireMELBOURNE, Australia, Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge mod
- 5y agoARHHAVCRFBABYFCLXPF+9Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingGlobeNewswireNEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased
- 5y agoSPHRYStarpharma to Webcast Live at Life Sciences Investor Forum June 24thGlobeNewswireMELBOURNE, Australia, June 24, 2021 (GLOBE NEWSWIRE) -- Starpharma ((ASX: SPL, OTCQX:SPHRY), based in Melbourne, Australia, today announced that Dr. Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInves
- 5y agoARHHAVCRFBABYFCLXPF+9Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021GlobeNewswireNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will s